DEXERYL Emollient Cream
Statistically significant effectiveness proven in clinical studies on over 1000 patients. These studies were conducted against a placebo or comparator, providing the highest level of scientific evidence
Regular application of Dexeryl Emollient Cream three times a day for 42 days significantly reduced the severity of radiotherapy-related erythema compared to a leading product¹
To compare the activity and tolerability of DEXERYL versus Trolamine in the management of post-radiotherapy erythema.
Phase III, single-centre, randomised (contralateral), double-blind study of Dexeryl cream versus Trolamine 0.67% (reference product).
80 randomised adult patients: 70 with breast cancer/10 with ENT cancer.
3 applications daily.
Duration of 12 weeks: 3 applications per day during the first 6 weeks of radiotherapy and then 6 weeks after it has finished.
Trophic aspect of treated skin surfaces at D42 (end of radiotherapy) assessed by clinical signs (pain, erythema, exulceration, exudation) using a semi-quantitative scale with 4 scores (0=absent, 1=slight, 2=moderate, 3=severe) and a visual analogue scale assessing the overall trophic aspect of the skin (0: skin lesion - 100: no skin lesion)
Tolerance is satisfactory for both products.
Cancer treatments can cause changes to the skin and nails.
How can you take care of your skin to minimise their occurrence?